Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05206357|
Recruitment Status : Recruiting
First Posted : January 25, 2022
Last Update Posted : November 28, 2023
The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). Initial treatment cures 90% - 95% of children with these malignancies, leaving a very small population of relapsed/refractory disease with a poor prognosis. The purpose of this study is to assess the safety and tolerability of epcoritamab in pediatric participants with relapsed/refractory aggressive mature B-cell neoplasms and young adult participants with Burkitt's or Burkitt-like lymphoma/leukemia. Adverse events and change in disease activity will be assessed.
Epcoritamab is an investigational drug being developed for the treatment of relapsed/refractory aggressive mature B-cell neoplasms. Participants will receive subcutaneous (SC) of epcoritamab. Approximately 15 pediatric participants with a diagnosis of relapsed/refractory aggressive mature B-cell neoplasms and and young adult participants, ages of 18-25, with a diagnosis of Burkitt's or Burkitt-like lymphoma/leukemia will be enrolled at 50 sites globally.
Participants will receive subcutaneous epcoritamab in 28-day cycles. Participants will be followed for a minimum of 3 years after enrollment.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
|Condition or disease||Intervention/treatment||Phase|
|Non-hodgkin Lymphoma||Drug: Epcoritamab||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms|
|Actual Study Start Date :||October 4, 2022|
|Estimated Primary Completion Date :||June 18, 2027|
|Estimated Study Completion Date :||June 18, 2027|
Participants will receive subcutaneous (SC) epcoritamab in 28 day cycles.
Subcutaneous Injection (SC)
Other Name: ABBV-GMAB-3013
- Number of Participants with Adverse Events (AE) [ Time Frame: Up to Approximately 3 Years ]An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
- Maximum Observed Concentration (Cmax) [ Time Frame: Up to Approximately Week 37 ]Maximum observed concentration.
- Area Under the Concentration Versus Time Curve (AUC) from Time 0 to Time of Last Measurable Concentration within the Dosing Interval (AUCtau) [ Time Frame: Up to Approximately Week 37 ]AUC from time 0 to time of last measurable concentration within the dosing interval.
- Percentage of Participants who Achieve Complete Response (CR) [ Time Frame: Up to Approximately 1 Year ]CR is defined per the International Pediatric Non-Hodgkin Lymphoma Response Criteria as computed tomography (CT) or magnetic resonance imaging (MRI) reveals no residual disease or new lesions; Resected residual mass that is pathologically (morphologically) negative for disease (detection of disease with more sensitive techniques); bone marrow (BM) and cerebrospinal fluid (CSF) morphologically free of disease (detection of disease with more sensitive techniques).
- Number of Participants with Event-free survival (EFS) [ Time Frame: Up to Approximately 3 Years ]EFS will be defined as the number of days from screening to the date of disease progression, treatment failure, or death from any cause.
- Number of Participants who Achieve Overall Survival (OS) [ Time Frame: Up to Approximately 3 Years ]OS will be defined as the number of days from screening to the date of death from any cause.
- Rate of Initiation of Stem Cell Transplantation or Chimeric Antigen Receptor T-cell (CAR-T) Therapy [ Time Frame: Up to Approximately 1 Year ]Rate of initiation of stem cell transplantation or CAR-T therapy.
- Percentage of Participants Achieving Overall Response (OR) [ Time Frame: Up to Approximately 1 Year ]OR is assessed as the percentage of participants with an overall response.
- Duration of response (DOR) [ Time Frame: Up to Approximately 1 Year ]DOR is defined as the time between the date of first response to the date of the first documented tumor progression or death due to any cause, whichever comes first.
- Duration of CR (DOCR) [ Time Frame: Up to Approximately 1 Year ]DOCR is defined as the time between the date of first CR to the date of the first documented tumor progression or death due to any cause, whichever comes first.
- Percentage of Participants Achieving Immunogenicity [ Time Frame: Up to Approximately Week 37 ]Immunogenicity is defined the percentage of participants with ADA and neutralizing anti-drug antibodies (nAb).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05206357
|Contact: ABBVIE CALL CENTERfirstname.lastname@example.org|
|Study Director:||ABBVIE INC.||AbbVie|